Evidence map›Paper›PMID 30854044›Full record

ArticleOncology letters2019

Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer.

Taxiarchis Konstantinos Nikolouzakis, Polychronis D Stivaktakis, Paraskevi Apalaki, Katerina Kalliantasi, Theodoros Mariolis Sapsakos, Demetrios A Spandidos, Aristidis Tsatsakis, John Souglakos, John Tsiaoussis

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Micronuclei: origins, assays, mechanisms, diseases and treatments.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Review
  5. Role of telomere length in human carcinogenesis (Review).International journal of oncology · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Taxiarchis Konstantinos NikolouzakisLaboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, 71110 Heraklion, Greece.
Polychronis D StivaktakisLaboratory of Toxicology, Medical School, University of Crete, 71409 Heraklion, Greece.
Paraskevi ApalakiDepartment of Forensic Sciences and Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.
Katerina KalliantasiDepartment of Forensic Sciences and Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.
Theodoros Mariolis SapsakosLaboratory of Anatomy and Histology, Nursing School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Demetrios A SpandidosLaboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece.
Aristidis TsatsakisDepartment of Forensic Sciences and Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece.
John SouglakosDepartment of Medical Oncology, University General Hospital of Heraklion, 71110 Heraklion, Greece.
John TsiaoussisLaboratory of Anatomy-Histology-Embryology, Medical School, University of Crete, 71110 Heraklion, Greece.
University of Crete · GRNational and Kapodistrian University of Athens · GRUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most diagnosed type of cancer affecting males, and the second most diagnosed type of cancer affecting females, and one of the leading causes of cancer-related mortality globally. The estimation of the micronuclei (MN) frequency in peripheral blood lymphocytes (PBLs) from patients with CRC is proposed as a prognostic/predictive easy-to-use biomarker. In this study, we aimed to investigate the effects of systemic treatment on the MN frequency in PBLs from patients with CRC in order to determine the effectiveness of the MN frequency as a biomarker. For this purpose, from 2016 to 2018, we quantified the MN frequency as a prognostic/predictive biomarker in serial samples from 25 patients with metastatic CRC (mCRC) using cytokinesis block micronucleus assay (CBMN assay). The MN frequency in the PBLs of the patients was evaluated before, during the middle and at the end of the therapy (approximately 0, 3 and 6 months). The results revealed a common pattern regarding the fluctuation in the MN frequency. Statistical analysis confirmed that when the disease response was estimated with radiological criteria, a good response was depicted at the MN frequency and vice versa. Consequently, the findings of this study suggest that the MN frequency may serve as a promising prognostic/predictive biomarker for the monitoring of the treatment response of patients with CRC.

Indexed as

cytokinesis block micronucleus assaymetastatic colorectal cancermicronuclei frequencymicronucleuspredictive biomarkerprognostic biomarker

Identifiers

PMID30854044
PMCPMC6365930
OpenAlexW2907898582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.